Menopause

A new study from the University of Colorado Boulder suggests that women who experience menopause at age 55 years or later may have significantly better vascular health and a reduced risk of heart attacks and strokes.

A new study found that menopausal hormone therapy is associated with a higher risk of systemic lupus erythematosus and systemic sclerosis, emphasizing the role of female sex hormones in immune-mediated diseases.

A new study published in Menopause suggests that white blood cell count could serve as a key predictor of COVID-19 symptom severity, highlighting the role of inflammation in health outcomes.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A recent study highlights worsened walking and motor skills in postmenopausal women with multiple sclerosis, shedding light on the need to determine hormone therapy benefits.

The OASIS 4 clinical trial showed successful reductions in the frequency and severity of hot flashes caused by adjuvant endocrine therapy used in breast cancer management.

The FDA has added a boxed warning for fezolinetant (VEOZAH; Astellas), highlighting the rare occurrence of serious liver injury in patients taking the menopause treatment.

Weak handgrip strength may predict diabetes risk in postmenopausal women, highlighting the importance of muscle strength in diabetes prevention.

In a recent study, an inverse relationship was discovered between anti-Müllerian hormone levels and early menopause, highlighting the need to develop interventions for fertility preservation based on genetics.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

In a recent study, menopausal women with frequent and time-consistent vasomotor symptoms were more likely to develop diabetes than those with reduced vasomotor symptoms.

Women experiencing menopause later in life may face an increased risk of asthma, according to recent research highlighting the impact of hormone levels on respiratory health.

The New Drug Application (NDA) acceptance is supported by positive data from 3 clinical trials (OASIS 1, 2, and 3).

In a recent study, postmenopausal women in lower Tertiles of Estradiol concentration experienced an increased prevalence of abdominal aortic calcification.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

In a recent study, only 22.7% of women had menopause symptoms documented in their electronic health record, highlighting low rates of diagnosis and treatment.

A recent study reveals that localized estrogen treatment significantly improves vaginal atrophy and vaginitis symptoms in postmenopausal women, offering new insights into tailored hormone therapies.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Matthew Nudy, MD, discusses his team's findings on hormone therapy and cardiovascular effects at the 2024 Annual Meeting of the Menopause Society.

Discover how deepening understanding and providing vetted resources can empower women to reclaim their wellness and navigate the powerful impacts of menopause with confidence.

New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.

Fezolinetant offers women a groundbreaking, non-hormonal solution to manage menopause symptoms like hot flashes and sleep disturbances, supported by large clinical trials.

A new study highlights gestational hypertension as a significant predictor of cardiovascular disease in menopausal women, challenging previous assumptions about preeclampsia’s role.

Research reveals that environmental exposures and PTSD from Gulf War service significantly increase the likelihood of early menopause, highlighting the need for targeted reproductive health care for women veterans.

Vanessa Muñiz presents research comparing clinical hypnosis and cognitive behavioral therapy for treating hot flashes, revealing that hypnosis significantly reduces frequency and improves quality of life.

Stephanie Faubion, MD, MBA, medical director of the Menopause Society, shares details from her presentation on hormone therapy at the 2024 Annual Meeting of The Menopause Society.

Lauren Streicher, MD, advocates for practical, individualized solutions for postmenopausal sexual dysfunction, emphasizing increased vascularization, stimulation, and addressing related symptoms.

PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.